About
Julian is a highly rated global M&A partner.
Julian has led many market defining transactions. He has topped M&A league tables on several occasions and won numerous deal awards. He combines this transactional work with strategic advice to boards of publicly traded companies on activism, succession planning, capital raisings, corporate governance and crisis and risk management.
Julian has a long-standing excellent reputation as a board adviser, reflecting his broad experience across a range of sectors and geographies. He is particularly valued by clients for his relationship skills, which are evident in his calming influence and reassuring manner.
Additional Information
Experience
- AstraZeneca on M&A transactions including the acquisition of Alexion and its defence of Pfizer’s bid.
- Sanofi on the sale of a 50% controlling stake in Opella to CD&R.
- Haleon on its spin from GSK.
- Novartis on its portfolio transformation.
- Comcast on its successful public auction against 21st Century Fox for Sky.
- Robey Warshaw on its sale to Evercore
- HSBC on a range of matters.
- Rentokil Initial on its acquisition of Terminix.
- Aon on various matters.
- BP on numerous matters.
- RELX on the simplification of its DLC structure and numerous M&A transactions.
- Cancer Research UK on the consortium arrangements behind the UK Centre for Medical Research and Innovation (UKCMRI).
Julian is an excellent, highly respected practitioner with a reassuring presence.
— Chambers | 2025
Julian Long
Partner
London Office
100 Bishopsgate
EC2P 2SR London